IF 1.2 4区 医学 Q3 OPHTHALMOLOGY
Jintong Liu, Rebecca G Edwards Mayhew, Lauren M Imbornoni, Jennifer L Jung, Scott C N Oliver, Nicholas K Foreman, Jean M Mulcahy Levy, Molly Hemenway, Emily A McCourt
{"title":"Pediatric MEK inhibitor-associated retinopathy: 8-year experience at a tertiary academic center and report of 2 cases.","authors":"Jintong Liu, Rebecca G Edwards Mayhew, Lauren M Imbornoni, Jennifer L Jung, Scott C N Oliver, Nicholas K Foreman, Jean M Mulcahy Levy, Molly Hemenway, Emily A McCourt","doi":"10.1016/j.jaapos.2025.104178","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>An adverse effect of mitogen-activated protein kinase (MEK) inhibitors is MEK inhibitor-associated retinopathy (MEKAR), a fluid collection between the retinal pigment epithelium (RPE) and interdigitation zone (IZ) seen in up to 90% of adults taking these medications. MEKAR is not well described in children. The purpose of this study was to characterize MEKAR screening practices, identify cases of MEKAR, and describe their clinical presentations in children.</p><p><strong>Methods: </strong>We conducted a retrospective study at our tertiary care pediatric hospital, examining pediatric patients who underwent MEK inhibitor (MEK-i) therapy between 2015 and 2023. We describe 2 cases of pediatric MEKAR that arose during the study period.</p><p><strong>Results: </strong>Of 152 patients identified, 104 met inclusion criteria. Trametinib was the most used MEK-i, with plexiform neurofibroma being the predominant indication for therapy. Optical coherence tomography macula screenings were predominantly performed in clinic, with varying screening intervals (mean, 9.85 months; median, 6.5 months). We identified 2 cases of pediatric MEKAR, both of which improved or resolved without altering MEK-i dosage. Our study suggests a lower rate of MEKAR in pediatric patients compared with adults, although limitations in screening frequency and duration may influence this observation.</p><p><strong>Conclusions: </strong>Our findings underscore the importance of systematic MEKAR screening protocols in pediatric patients receiving MEK-i therapy, facilitating early detection and monitoring of ocular toxicity. When MEKAR develops, the risks of stopping treatment must be weighed against the risks of retinopathy, although in our patients, MEKAR resolved without alterations to their medication regimen.</p>","PeriodicalId":50261,"journal":{"name":"Journal of Aapos","volume":" ","pages":"104178"},"PeriodicalIF":1.2000,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Aapos","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jaapos.2025.104178","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:丝裂原活化蛋白激酶(MEK)抑制剂的一个不良反应是MEK抑制剂相关视网膜病变(MEKAR),即视网膜色素上皮细胞(RPE)和连接区(IZ)之间的液体聚集,在服用此类药物的成人中,这种情况高达90%。而 MEKAR 在儿童中的描述并不详尽。本研究旨在了解 MEKAR 筛查方法的特点,确定 MEKAR 病例,并描述其在儿童中的临床表现:我们在我们的三级儿科医院开展了一项回顾性研究,对2015年至2023年间接受MEK抑制剂(MEK-i)治疗的儿科患者进行了检查。我们描述了研究期间出现的2例儿科MEKAR病例:在确定的152例患者中,有104例符合纳入标准。曲美替尼是使用最多的MEK-i,丛状神经纤维瘤是主要的治疗适应症。光学相干断层扫描黄斑筛查主要在临床中进行,筛查间隔时间各不相同(平均为 9.85 个月;中位数为 6.5 个月)。我们发现了 2 例小儿 MEKAR 病例,这 2 例病例均在不改变 MEK-i 剂量的情况下得到改善或缓解。我们的研究表明,与成人相比,儿科患者的 MEKAR 发生率较低,但筛查频率和持续时间的限制可能会影响这一观察结果:我们的研究结果强调了在接受MEK-i治疗的儿童患者中开展系统性MEKAR筛查方案的重要性,这有助于早期发现和监测眼部毒性。当出现 MEKAR 时,必须权衡停止治疗的风险和视网膜病变的风险,尽管在我们的患者中,MEKAR 在不改变用药方案的情况下就得到了缓解。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Pediatric MEK inhibitor-associated retinopathy: 8-year experience at a tertiary academic center and report of 2 cases.

Background: An adverse effect of mitogen-activated protein kinase (MEK) inhibitors is MEK inhibitor-associated retinopathy (MEKAR), a fluid collection between the retinal pigment epithelium (RPE) and interdigitation zone (IZ) seen in up to 90% of adults taking these medications. MEKAR is not well described in children. The purpose of this study was to characterize MEKAR screening practices, identify cases of MEKAR, and describe their clinical presentations in children.

Methods: We conducted a retrospective study at our tertiary care pediatric hospital, examining pediatric patients who underwent MEK inhibitor (MEK-i) therapy between 2015 and 2023. We describe 2 cases of pediatric MEKAR that arose during the study period.

Results: Of 152 patients identified, 104 met inclusion criteria. Trametinib was the most used MEK-i, with plexiform neurofibroma being the predominant indication for therapy. Optical coherence tomography macula screenings were predominantly performed in clinic, with varying screening intervals (mean, 9.85 months; median, 6.5 months). We identified 2 cases of pediatric MEKAR, both of which improved or resolved without altering MEK-i dosage. Our study suggests a lower rate of MEKAR in pediatric patients compared with adults, although limitations in screening frequency and duration may influence this observation.

Conclusions: Our findings underscore the importance of systematic MEKAR screening protocols in pediatric patients receiving MEK-i therapy, facilitating early detection and monitoring of ocular toxicity. When MEKAR develops, the risks of stopping treatment must be weighed against the risks of retinopathy, although in our patients, MEKAR resolved without alterations to their medication regimen.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Aapos
Journal of Aapos 医学-小儿科
CiteScore
2.40
自引率
12.50%
发文量
159
审稿时长
55 days
期刊介绍: Journal of AAPOS presents expert information on children''s eye diseases and on strabismus as it affects all age groups. Major articles by leading experts in the field cover clinical and investigative studies, treatments, case reports, surgical techniques, descriptions of instrumentation, current concept reviews, and new diagnostic techniques. The Journal is the official publication of the American Association for Pediatric Ophthalmology and Strabismus.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信